Opportunities and Challenges of Safety Biomarker Qualification: Perspectives from the Predictive Safety Testing Consortium
The advantages of frontotemporal degeneration drug development (Part 2 of frontotemporal degeneration: the next therapeutic frontier)
Global standardization measurement of cerebral spinal fluid for Alzheimer’s disease: an update from the Alzheimer’s Association Global Biomarkers Consortium
Understanding Placebo Responses in Alzheimer’s Disease Clinical Trials from the Literature Meta-Data and CAMD Database
January 12, 2012 Recommendations For Incorporating Patient-Reported Outcomes Into Clinical Comparative Effectiveness Research In Adult Oncology